Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy

NCT01521975 is registered in ClinicalTrials.gov with Third Affiliated Hospital, Sun Yat-Sen University as lead sponsor.

NCT NCT01521975
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01521975 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Two-year, Open-label, Virological Response Adaptive Design, Multicenter Study to Evaluate Efficacy of Telbivudine in HBeAg Negative Adult CHB Patients With Roadmap Strategy
Lead sponsor
Third Affiliated Hospital, Sun Yat-Sen University
Phase
Phase 4
Overall status
Completed
Start date
January 1, 2011
Completion date
May 30, 2014
Enrollment
360 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis b, chronic